Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium

Core Insights - Autonomix Medical, Inc. has presented new clinical data showing significant pain relief in pancreatic cancer patients across all disease stages, emphasizing the effectiveness of their nerve-targeted treatment approach [1][2][4]. Group 1: Clinical Findings - The post hoc subgroup analysis from the ongoing Proof-of-Concept study indicates consistent pain reduction in pancreatic cancer patients treated with a transvascular RF denervation platform, regardless of disease severity [2]. - Rapid onset of pain relief was observed, with patients showing marked reduction in average pain within 24 hours post-procedure [6]. - At 7 days post-procedure, 93.75% of responding patients improved from severe pain to mild or moderate pain, with some achieving near-elimination of pain [6]. - Sustained benefits were noted, with approximately two-thirds of responding patients maintaining mild or eliminated pain levels at 4-6 weeks post-procedure [6]. - At 3 months post-procedure, no responding patients reported severe pain, and 50% maintained mild or eliminated pain levels [6]. - Notably, even late-stage (Stage 4) cancer patients experienced meaningful pain relief, transitioning from severe to mild or moderate pain [6]. Group 2: Presentation Details - The findings were presented at the 2026 ASCO Gastrointestinal Cancers Symposium, under the poster titled "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation" [4][5]. - The presentation was made by Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc., during Poster Session B [5]. Group 3: Company Overview - Autonomix Medical, Inc. focuses on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, with a first-in-class platform system technology that includes a catheter-based microchip sensing array [6][8]. - The company is initially developing its technology for pain treatment, particularly targeting pancreatic cancer, which is known for causing debilitating pain and lacking reliable solutions [8].